Page last updated: 2024-08-23

daunorubicin and tandutinib

daunorubicin has been researched along with tandutinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Heinrich, MC; Kampa, KM; Schittenhelm, MM; Yee, KW	1

Other Studies

1 other study(ies) available for daunorubicin and tandutinib

Article	Year
The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. Cell cycle (Georgetown, Tex.), 2009, Aug-15, Volume: 8, Issue:16 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines	2009

Article

Year

The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.

Cell cycle (Georgetown, Tex.), 2009, Aug-15, Volume: 8, Issue:16

Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Proliferation; Cytarabine; Daunorubicin; Drug Synergism; Flow Cytometry; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Piperazines; Quinazolines

2009